Company registration number 08085378 (England and Wales)
DANBURYKLINE LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025
PAGES FOR FILING WITH REGISTRAR
DANBURYKLINE LIMITED
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 8
DANBURYKLINE LIMITED
BALANCE SHEET
AS AT
31 MAY 2025
31 May 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
4
17,886
26,325
Current assets
Debtors
5
529,362
402,344
Cash at bank and in hand
1,186,014
1,254,701
1,715,376
1,657,045
Creditors: amounts falling due within one year
6
(316,721)
(310,125)
Net current assets
1,398,655
1,346,920
Total assets less current liabilities
1,416,541
1,373,245
Provisions for liabilities
90,467
100,170
Net assets
1,507,008
1,473,415
Capital and reserves
Called up share capital
600
600
Other reserves
438,488
425,023
Profit and loss reserves
1,067,920
1,047,792
Total equity
1,507,008
1,473,415

For the financial year ended 31 May 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 23 December 2025 and are signed on its behalf by:
Mr W Jenner
Mr R Spence
Director
Director
Company registration number 08085378 (England and Wales)
DANBURYKLINE LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MAY 2025
- 2 -
Share capital
Share based payment reserve
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 June 2023
600
379,183
748,035
1,127,818
Year ended 31 May 2024:
Profit and total comprehensive income for the year
-
-
299,757
299,757
Share based payment options
-
45,840
-
0
45,840
Balance at 31 May 2024
600
425,023
1,047,792
1,473,415
Year ended 31 May 2025:
Profit and total comprehensive income for the year
-
-
120,128
120,128
Dividends
-
-
(100,000)
(100,000)
Share based payment options
-
13,465
-
0
13,465
Balance at 31 May 2025
600
438,488
1,067,920
1,507,008
DANBURYKLINE LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2025
- 3 -
1
Accounting policies
Company information

DanburyKline Limited is a private company limited by shares incorporated in England and Wales. The registered office is Suite 3 Ground Floor, Andrews House, College Road, Guildford, England, GU1 4QB.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention (with the exception of share-based payments, which are measured at fair value). The principal accounting policies adopted are set out below.

1.2
Going concern

A true t the time of approving the financial statements, t he directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus t he directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from subscription based services if recognised in the period the service is provided. Revenue from consultancy based services is recognised as and when provided.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings
33% straight line
Fixtures and fittings
20% straight line
Computers
33% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

DANBURYKLINE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2025
1
Accounting policies
(Continued)
- 4 -
1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

DANBURYKLINE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2025
1
Accounting policies
(Continued)
- 5 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12
Share-based payments

Equity-settled share-based payments are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted using the black scholes model. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the estimate of shares that will eventually vest. A corresponding adjustment is made to equity, if material.

When the terms and conditions of equity-settled share-based payments at the time they were granted are subsequently modified, the fair value of the share-based payment under the original terms and conditions and under the modified terms and conditions are both determined at the date of the modification. Any excess of the modified fair value over the original fair value is recognised over the remaining vesting period in addition to the grant date fair value of the original share-based payment. The share-based payment expense is not adjusted if the modified fair value is less than the original fair value.

Cancellations or settlements (including those resulting from employee redundancies) are treated as an acceleration of vesting and the amount that would have been recognised over the remaining vesting period is recognised immediately.

DANBURYKLINE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2025
1
Accounting policies
(Continued)
- 6 -
1.13
Leases
As lessee

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

1.14

Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

The following judgements (apart from those involving estimates) have had the most significant effect on amounts recognised in the financial statements.

Share based payment options - Vesting period

Share based payments awarded are exercisable upon an exit event. To determine the vesting period the directors are required to estimate the timing of such an event and the expected number of employees who currently hold options remaining at the company. For 2025, the directors believe a sale to not be imminent and so the vesting period has reverted to the remainder of the original 10 year period.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
25
22
DANBURYKLINE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2025
- 7 -
4
Tangible fixed assets
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 June 2024
8,715
49,389
58,104
Additions
-
0
4,955
4,955
Disposals
(8,715)
(7,136)
(15,851)
At 31 May 2025
-
0
47,208
47,208
Depreciation and impairment
At 1 June 2024
8,633
23,146
31,779
Depreciation charged in the year
82
13,223
13,305
Eliminated in respect of disposals
(8,715)
(7,047)
(15,762)
At 31 May 2025
-
0
29,322
29,322
Carrying amount
At 31 May 2025
-
0
17,886
17,886
At 31 May 2024
82
26,243
26,325
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
397,341
377,665
Corporation tax recoverable
56,928
15,742
Other debtors
4,833
2,417
Prepayments and accrued income
70,260
6,520
529,362
402,344
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
27,596
164
Taxation and social security
167,836
184,580
Other creditors
-
0
842
Accruals and deferred income
121,289
124,539
316,721
310,125
DANBURYKLINE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MAY 2025
- 8 -
7
Share-based payment transactions

As part of its long term incentive policy Danburykline Limited initiated a number of share option schemes for key employees. The share options are subject to the service and performance conditions of the scheme. The fair value of the share options granted is recognised as a staff cost with a corresponding adjustment to equity over the period during which the employees become unconditionally entitled to the options (vesting period). The options only vest on sale of the business. The directors estimated that an exit event would happen after 10 years when issued.

The expense is based upon the company's estimates of fair value of the acquired equity instruments using a Black-Scholes option pricing model in accordance with the conditions of granting.

Number of share options
Weighted average exercise price
2025
2024
2025
2024
Number
Number
£
£
Outstanding at 1 June 2024 and 31 May 2025
240
240
243.67
243.67
Exercisable at 31 May 2025
-
0
-
0
-
0
-
0

The options outstanding at 31 May 2025 had an exercise price ranging from £230.67 to £295.67, and a remaining contractual life of 3-4 years.

Liabilities and expenses

During the year, the company recognised total share-based payment expenses of £13,465 (2024 - £45,840) which related to equity settled share based payment transactions.

8
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2025
2024
£
£
In less than one year
48,893
48,893
Between two and five years
36,669
85,562
85,562
134,455
2025-05-31 2024-06-01 false false false 23 December 2025 CCH Software CCH Accounts Production 2025.200 No description of principal activity Mr W Jenner Mr R Spence 08085378 2024-06-01 2025-05-31 08085378 2025-05-31 08085378 2024-05-31 08085378 core:LandBuildings 2025-05-31 08085378 core:OtherPropertyPlantEquipment 2025-05-31 08085378 core:LandBuildings 2024-05-31 08085378 core:OtherPropertyPlantEquipment 2024-05-31 08085378 core:ShareCapital 2025-05-31 08085378 core:ShareCapital 2024-05-31 08085378 core:OtherMiscellaneousReserve 2025-05-31 08085378 core:OtherMiscellaneousReserve 2024-05-31 08085378 core:RetainedEarningsAccumulatedLosses 2025-05-31 08085378 core:RetainedEarningsAccumulatedLosses 2024-05-31 08085378 core:ShareCapital 2023-05-31 08085378 core:OtherMiscellaneousReserve 2023-05-31 08085378 core:RetainedEarningsAccumulatedLosses 2023-05-31 08085378 2023-05-31 08085378 bus:Director1 2024-06-01 2025-05-31 08085378 bus:Director2 2024-06-01 2025-05-31 08085378 core:RetainedEarningsAccumulatedLosses 2023-06-01 2024-05-31 08085378 2023-06-01 2024-05-31 08085378 core:RetainedEarningsAccumulatedLosses 2024-06-01 2025-05-31 08085378 core:LandBuildings core:LongLeaseholdAssets 2024-06-01 2025-05-31 08085378 core:FurnitureFittings 2024-06-01 2025-05-31 08085378 core:ComputerEquipment 2024-06-01 2025-05-31 08085378 core:LandBuildings 2024-05-31 08085378 core:OtherPropertyPlantEquipment 2024-05-31 08085378 2024-05-31 08085378 core:LandBuildings 2024-06-01 2025-05-31 08085378 core:OtherPropertyPlantEquipment 2024-06-01 2025-05-31 08085378 core:CurrentFinancialInstruments 2025-05-31 08085378 core:CurrentFinancialInstruments 2024-05-31 08085378 core:WithinOneYear 2025-05-31 08085378 core:BetweenTwoFiveYears 2025-05-31 08085378 bus:PrivateLimitedCompanyLtd 2024-06-01 2025-05-31 08085378 bus:SmallCompaniesRegimeForAccounts 2024-06-01 2025-05-31 08085378 bus:FRS102 2024-06-01 2025-05-31 08085378 bus:AuditExemptWithAccountantsReport 2024-06-01 2025-05-31 08085378 bus:FullAccounts 2024-06-01 2025-05-31 xbrli:pure xbrli:shares iso4217:GBP